UK expects to save 75% from adalimumab rivals
Savings of around 75% on the cost of adalimumab are expected by the UK’s National Health Service (NHS) “after negotiating deals with five manufacturers on low-cost versions of the health service’s most costly drug”. The NHS said it had “moved swiftly to drive strong competition between biosimilar manufacturers and the manufacturer of the originator brand, resulting in huge cost discounts”.
You may also be interested in...
Organon CEO Kevin Ali has suggested that discounts for US Humira biosimilars could “range anywhere between 80% and 90%” by 2025-2026, amid a slew of competition on adalimumab starting within weeks.
The advent of US biosimilar competition to Humira in 2023 represents the largest ever loss-of-exclusivity opportunity for the off-patent industry, with the first adalimumab rival expected to hit the US market at the end of this month. But with a host of other biosimilars expected to launch throughout the year, how will competition play out in the long term?
The advent of biosimilar competition to Humira in the US in 2023 represents the largest loss-of-exclusivity opportunity ever for the off-patent industry. But with a host of biosimilar sponsors awaiting launches throughout the year, it remains to be seen how competition will play out.